Acknowledgments The idea for this post was based upon the research by Dr. Lloyd Bridge, presented at the British Pharmacological Society meeting December 2018. and published in October 2020 in …
The correct reporting of pharmacokinetic data can provide a tremendous amount of information on the clinical pharmacological characteristics of a drug. Small studies with a limited number of plasma samples …
Introduction We are not all the same. We know that there is variability originating from physiological differences in the pharmacokinetic and pharmacodynamic (PK/PD) processes between individuals in a population, also …
This post is based on the work of, among others, Camille Vong and the hands-on course about the MCMP given by Rob ter Heine and Elin Svensson. Read and cite …
How do we develop a ‘standard’ population PK model? We obtain blood/plasma concentrations over time of the drug of interest, in multiple individuals, and we apply our population NLME modelling …
In 2019 alone, PMXSolutions.com has been visited by over 15.000 visitors! In order to celebrate this overwhelming interest in the website, I have made the Shiny application for pharmacokinetic simulations …
A modellers challenge: getting data in front of you that don’t seem to fit any of the standard effect models and PKPD relationships. Especially in endocrinology, hormonal profiles are rarely …
In previous posts we referred exclusively to modelling using the top-down, population approach. However, in recent years, physiology-based, bottom-up approaches are getting more attention from both industry and regulators. Population …
The identification of hysteresis in a PK/PD relationship provides information on a possible delay between the plasma concentration and the effect. The identification of hysteresis can further assist us in …
Introduction Why do we assume symmetry in our concentration-effect relationship? I recently came across an article published by Piet Hein van der Graaf and Rik Schoemaker from 1999 on the …
